ArticleEuropean journal of nuclear medicine and molecular imaging2022
Preclinical investigations using [
Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Tolerability of [European journal of nuclear medicine and molecular imaging · 2026Article
- Coumarin Conjugation as an Albumin-Binding Strategy to Modulate the Pharmacokinetics of FAPI Radiotracers.ACS omega · 2026Article
- Effective treatment of human prostate carcinoma xenografts with Single-Dose PSMA-targeted [European journal of nuclear medicine and molecular imaging · 2026Article
- Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope.Drug design, development and therapy · 2026Review
- Therapeutic evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025Article
- Design and characterization of a novel prostate-specific membrane antigen-targeted radioligand modified with a fatty acid albumin binder for optimized circulation half-life.EJNMMI radiopharmacy and chemistry · 2025Article
- Biodistribution and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Advances in PSMA-Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancer management and research · 2025Review
- Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform.EJNMMI radiopharmacy and chemistry · 2024Article
- Comparison of the tolerability ofEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Prostate-Specific Membrane Antigen Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer.Advanced healthcare materials · 2024Article
- Hematological and renal toxicity in mice after three cycles of high activity [Scientific reports · 2024Article
- Review
- Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Theranostics - a sure cure for cancer after 100 years?Theranostics · 2024Review
- Pharmacological Profile of Novel Anti-cancer Drugs Approved by USFDA in 2022: A Review.Current molecular medicine · 2024Review
- Effective Treatment of SSTR2-Positive Small Cell Lung Cancer UsingMolecular pharmaceutics · 2023Article
- Preclinical Evaluation of a New Series of Albumin-BindingMolecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.